Evidence map›Paper›PMID 25681572›Full record

ReviewExperimental neurology2015

Pathways regulating modality-specific axonal regeneration in peripheral nerve.

Matthew D Wood, Susan E Mackinnon

Abstract readReview
In one paragraph

Review in Experimental neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. ComprehensiveFrontiers in bioengineering and biotechnology · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Robo2 Drives Target-Selective Peripheral Nerve Regeneration in Response to Glia-Derived Signals.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew D WoodDivision of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, Campus Box 8238, 660 South Euclid Avenue, St. Louis, MO 63110, USA. Electronic address: woodm@wudosis.wustl.edu.
Susan E MackinnonDivision of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, Campus Box 8238, 660 South Euclid Avenue, St. Louis, MO 63110, USA. Electronic address: mackinnon@wudosis.wustl.edu.

Funding

THE EFFECTS OF GDNF ON PERIPHERAL NERVE REGENERATIONR01NS051706 · NINDS · WASHINGTON UNIVERSITY · PI MACKINNON, SUSAN E, SAKIYAMA-ELBERT, SHELLY ELESE · 2006 to 2016
$4.0M
NINDS NIH HHS R01 NS051706
6 · The paper itself

Abstract

Following peripheral nerve injury, the distal nerve is primed for regenerating axons by generating a permissive environment replete with glial cells, cytokines, and neurotrophic factors to encourage axonal growth. However, increasing evidence demonstrates that regenerating axons within peripheral nerves still encounter axonal-growth inhibitors, such as chondroitin sulfate proteoglycans. Given the generally poor clinical outcomes following peripheral nerve injury and reconstruction, the use of pharmacological therapies to augment axonal regeneration and overcome inhibitory signals has gained considerable interest. Joshi et al. (2014) have provided evidence for preferential or modality-specific (motor versus sensory) axonal growth and regeneration due to inhibitory signaling from Rho-associated kinase (ROCK) pathway regulation. By providing inhibition to the ROCK signaling pathway through Y-27632, they demonstrate that motor neurons regenerating their axons are impacted to a greater extent compared to sensory neurons. In light of this evidence, we briefly review the literature regarding modality-specific axonal regeneration to provide context to their findings. We also describe potential and novel barriers, such as senescent Schwann cells, which provide additional axonal-growth inhibitory factors for future consideration following peripheral nerve injury.

Indexed as

AnimalsAxonsHumansNerve RegenerationNeural PathwaysPeripheral Nerve InjuriesPeripheral NervesAxon modalityChondroitin sulfate proteoglycanMotor neuronNerve regenerationPeripheral nerveRhoAROCKSchwann cellSensory neuronY-27632

Identifiers

PMID25681572
PMCPMC4399493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.